For more information on our current clinical trials, click here.

Prostate cancer research at Columbia University has a long and rich history.  Because of the groundbreaking work in prostate cancer, it is one of the four disease-specific programs at the Herbert Irving Comprehensive Cancer Center, a National Cancer Institute designated Comprehensive Cancer Center.  Research led by Columbia investigators resulted in the approval of docetaxel chemotherapy as the first chemotherapeutic agent to prolong survival in metastatic prostate cancer in 2004.  Ongoing innovative research to understand the underlying factors behind prostate cancer biology has led to findings that may help to predict the aggressiveness of prostate cancer.  And ongoing exciting clinical research is translating the basic science findings into new treatments and hopefully a cure.